The pain won’t stop. GSK ends the week with a slapdown on its Nucala application for COPD

At a time the company is hoping to begin to demonstrate that the pharma R&D group has begun a long-awaited turnaround, the FDA just completed its latest humiliation on a new application for Nucala with a widely expected complete response letter.